- Home
- UCAR vs NCNA Comparison
UCAR vs NCNA Comparison
Compare UCAR & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UCAR | NCNA |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 7.6M |
| IPO Year | 2023 | 2017 |
Fundamental Metrics
Financial Performance| Metric | UCAR | NCNA |
|---|---|---|
| Price | $1.74 | $3.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 22.4K | ★ 65.1K |
| Earning Date | 10-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,816,075.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 57.22 | N/A |
| 52 Week Low | $1.71 | $2.78 |
| 52 Week High | $9.43 | $330.00 |
Technical Indicators
Market Signals| Indicator | UCAR | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 39.34 | 43.98 |
| Support Level | $1.71 | $4.10 |
| Resistance Level | $1.91 | $4.55 |
| Average True Range (ATR) | 0.10 | 0.30 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 33.96 | 20.95 |
Price Performance
Historical ComparisonAbout UCAR U Power Limited
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.